BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) w
BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) whose disease had progressed despite sorafenib therapy in the phase 3 CELESTIAL trial reported to the 2018 ESMO World Congress on Gastrointesinal Cancer.
http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.207
“This is a new oral drug [that’s] very easy for the patient to take at home. And it works for some patients. When it works it can work very well. It can prolong life—and with very good responses in some patients in terms of tumor necrosis, tumor shrinkage, tumor de-vascularization. It’s well tolerated and it’s a new tool to fight against cancer,” according to study co-author Philippe Merle MD PhD, a hepato-gastro oncologist and medical oncologist at the Hospice Civile de Lyon University Hospital in Lyon, France. He discusses the CELESTIAL trial and it’s clinical implications with the Audio Journal of Oncology’s Sarah Maxwell.
Tags
Related Episodes
Trevor Leong MD: Operable Gastric or GE-Junction Adenocarcinoma: No Advantage from Neoadjuvant Radiotherapy
resectable-gastric-and-ge-junction adenocarcinoma-radiation-therapy-no-help
Yelena Janjigian ASCO Plenary: Peri-Operative Chemo-Immunotherapy Delays Recurrence in Patients with Gastric or GE Junction Cancers
Yelena Y. Janjigian MD says that perioperative anti-PD-L1 immunotherapy with durvalumab was a “game changer” meriting use as a new standard of care when used together with chemotherapy to
Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer
BARCELONA—A chemotherapy combination consisting of trifluridine with tipiracil showed a “clinically meaningful and statistically significant” improvement in overall survival (OS) and progr